`
`achieves a high level of efficacy that is non-inferior to the standard of care.'
`
`for that particuIarangiogenic eye disorder, at the time of patent filing], said
`
`method comprising sequentially administering to the patient a single initial dose
`
`of a VEGF antagonist, followed by one or more secondary doses of the VEGF
`
`antagonist, followed by one or more [dosesad ministered after _the initial and
`
`econdarydoses,' that—maintain _the efficacy gained after the initial and
`
`secondary doses] of the VEGF antagonist;
`
`wherein each secondary dose is administered 2 to 4 weeks after the
`
`immediately preceding dose; and
`
`wherein each [dose, administered after the -initial -and secondarydoses
`
`that maintains the _efficacy ,
`
`1oses] is administered at least 8 weeks after the immediately preceding
`
`dose;
`
`wherein the VEGF antagonist is a VEGF receptor-based chimeric molecule
`
`comprising (1) a \TEGFR1 component comprising amino acids 27 to 129
`
`of SEQ ID NO:2; (2) a VEGFR2 component comprising amino acids
`
`130-231 of SEQ ID NO:2; and (3) a multimerization component
`
`comprising amino acids 232-457of SEQ ID NO:2.
`
`O EXHIBIT '1
`WITNESS: Do
`DATE:
`
`
`Anrae Wimberley, CSR 7778
`
`Mylan Exhibit 1138
`Mylan v. Regeneron, IPR2021-00881
`Page 1
`
`